Form 4: Amarin COO Keenan's Equity Transactions Post-ADS Ratio Change

Amarin's COO, David Paul Keenan, reported the vesting of 3,688 Restricted Stock Units and subsequent tax-related share withholding, resulting in a net increase in his direct beneficial ownership of American Depositary Shares.

Summary

• David Paul Keenan, EVP, Chief Operating Officer of Amarin Corp PLC\UK, reported transactions on January 2, 2026.
• 3,688 American Depositary Shares (ADS) were acquired due to the vesting of Restricted Stock Units (RSUs).
• 1,926 ADS were disposed of to cover tax liabilities related to the RSU vesting, at a price of $13.96 per share.
• Following these transactions, Keenan directly beneficially owns 9,712 ADS.
• The reported amounts reflect an ADS Ratio Change effective April 11, 2025, where one ADS now represents twenty Ordinary Shares.
• Keenan was granted 7,376 RSUs on January 10, 2025, with 50% (3,688 RSUs) vesting on January 2, 2026, and the remaining 50% vesting on July 1, 2026.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The vesting of RSUs and subsequent net increase in beneficial ownership for a key executive is generally seen as a positive sign of alignment and confidence, though the tax-related sale is a routine event.

Positives

• Vesting of 3,688 Restricted Stock Units indicates continued long-term incentive alignment between management and shareholders.
• The net increase in beneficial ownership (3,688 acquired, 1,926 disposed for tax, resulting in a net increase of 1,762 ADS) suggests management confidence.

Negatives

• Disposal of 1,926 American Depositary Shares to cover tax liabilities, while a common practice, reduces the direct equity holding.

Future Outlook

The filing indicates future vesting events, with the remaining 50% of the 2025 RSU grant scheduled to vest on July 1, 2026, suggesting continued long-term incentive alignment.

Industry Context

This Form 4 filing is a routine disclosure of executive equity transactions and does not provide broader industry context. It reflects standard executive compensation practices involving equity awards in publicly traded pharmaceutical companies like Amarin.

Comparison to Industry Standards

• The RSU vesting and subsequent tax withholding are standard practices for executive compensation in the pharmaceutical industry.
• The ADS ratio change is an internal corporate action, not directly comparable to industry performance benchmarks. No specific comparable companies or projects are mentioned in this filing.

Stakeholder Impact

• Shareholders: The vesting and retention of shares by a key executive can be viewed positively as it aligns management's interests with shareholder value.
• Employees: This filing specifically relates to executive compensation and does not directly impact the broader employee base, though it reflects the company's equity incentive plans.

Next Steps

• Remaining 3,688 Restricted Stock Units are scheduled to vest on July 1, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine executive equity transaction involving RSU vesting and tax withholding. It does not contain information that would fundamentally alter the investment thesis for Amarin. The net increase in the COO's direct beneficial ownership is a minor positive, indicating continued alignment, but it's not a strong catalyst for a 'buy' or 'sell' recommendation. Therefore, a 'hold' recommendation is appropriate as this filing provides no new material information to change an existing position.

Keywords

Amarin, AMRN, Form 4, Insider Trading, Restricted Stock Units, RSU, American Depositary Shares, ADS, Executive Compensation, Equity Vesting, David Paul Keenan, Officer Transaction